MISONIX, Inc. (NASDAQ:MSON) is expected to report fourth quarter earnings results, after market close, on Thursday 3rd September 2020.
Analysts polled by Thomson Reuters anticipate fourth quarter loss of $ 0.48 per share.
Looking ahead, the full year loss are expected at $ 1.16 per share on the revenues of $ 58.30 million.
The Company Outlook
Revenue for 4Q20 are expected in a range of $ 13.50 million ~ $ 13.50 million
Full Year 2020 topline are forecasted in a range of$ 70.70 million ~ $ 70.70 million
Click Here For More Historical Outlooks Of MISONIX, Inc.
Previous Quarter Performance
MISONIX, Inc. posted loss for the third quarter of $ 0.34 per share, from the revenue of $ 17.90 million. Wall street analysts are predicting, MSON to report 3Q20 loss of $ 0.32 per share from revenue of $ 18.58 million. The bottom line results missed street analysts by $ 0.02 or 6.25 percent, at the same time, top line results fell short of analysts by $ 0.68 million or 3.66 percent.
Stock Performance
Shares of MISONIX, Inc. traded up $ 0.21 or 1.64 percent on Wednesday, reaching $ 12.99 with volume of 28.30 thousand shares. The stock opened down for the day at $ 12.69, after closing the previous day trading at $ 12.78.
According to the previous trading day, closing price of $ 12.78, representing a 90.46 % increase from the 52 week low of $ 6.71 and a 42.43 % decrease over the 52 week high of $ 22.20.
The company has a market capital of $ 225.53 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
MISONIX, Inc. will be hosting a conference call at 4:30 PM eastern time on 3rd September 2020, to discuss its 4Q20 financial results with the investment community. The participants may dial, 800-437-2398 (United States) or 323-289-6576 (International), when prompted, enter passcode 8353775 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website edge.media-server.com/mmc/p/74g4drra
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgical applications.
